Lifeward (LFWD)
Powered exoskeletons and anti-gravity treadmills for mobility and rehabilitation.
Something off on this page? Send us feedback.
Develops ReWalk personal exoskeletons and AlterG Anti-Gravity Treadmills, generating primarily equipment revenue plus related service, support, and rentals; its U.S. exoskeleton business depends on payer coverage, approvals, and collection timing.
Develops powered mobility and rehabilitation devices, centered on the ReWalk Personal Exoskeleton for people with spinal-cord injuries and AlterG Anti-Gravity Treadmills for rehabilitation clinics, hospitals, and sports organizations. The portfolio also includes MyoCycle functional-electrical-stimulation bikes and the ReStore gait-training exosuit; newly acquired upper-body exoskeleton technology and an oral protein-delivery platform remain in development.
Revenue is principally equipment sales, complemented by AlterG service and support and ReWalk rentals that can lead to sales in Germany. Direct sales cover the United States and Germany while distributors serve other markets. ReWalk economics depend on payer coverage, approvals, collection timing, clinical training, and regulatory authorizations; AlterG shipments depend on manufacturing and inventory availability.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 21, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $13 | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.4M · Total debt $11.1M · Total assets $35.0M · Shareholders' equity $12.2M
- Revenue
- $6.6M
- Operating income
- −$4.2M
- Net income
- −$11.5M
No dividends on record.
| Institutions | 1.99% | 32.1K shares | |
|---|---|---|---|
| 8 holders · as of Jun 30, 2026 | |||
| Insiders | 8.99% | 144.9K shares | |
| 17 holders · as of Sep 10, 2026 | |||
| Strategic holders | 99.30% | 1.60M shares | |
| 2 holders · as of May 14, 2026 | |||
| Adds to | 110.28% | ||
1.61M company shares as of Sep 8, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (2.83M in the company's Sep 22, 2026 report, 1.61M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 110.28%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Oramed Pharmaceuticals Inc.Strategic10 percent owner | 94.86% | 1.53M | filed May 14, 2026 |
Lind Global Fund II LP1Strategic10 percent owner | 4.44% | 71,500 | filed Jan 8, 2025 |
Citadel Advisors LLCInstitution | 1.12% | 18,064 | as of Jun 30, 2026 |
Keith Dale RoseInsiderofficer: Chief Medical Officer | 1.06% | 17,083 | filed May 20, 2026 |
Avraham GabayInsiderdirector | 0.85% | 13,643 | filed Aug 24, 2026 |
- Reported at 1.70% on May 15, 2025, under the 5% line, so no further filing is required.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Ekso Bionics
Robotic exoskeleton alternative in hospital and outpatient gait rehabilitation.
- Mirion Technologies
Unweighting and gait-training alternative for rehabilitation facilities.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lifeward | $7.09 | +1.29% | $11.3M | — | — | 0.5 | +15.7% |
| Ekso Bionics | $15.90 | −9.86% | $38.6M | — | — | 3.3 | −36.6% |
| Mirion Technologies | $16.41 | +1.23% | $3.94B | 173.2 | 27.8 | 3.8 | +19.7% |
| Median | 173.2 | 27.8 | 3.6 | −8.4% |